Bulletin
Investor Alert

New York Markets Open in:

Quidel Corp.

NAS: QDEL

GO
/marketstate/country/us

Before the Bell

 --Quotes are delayed by 20 min

Apr 19, 2021, 4:17 a.m.

/zigman2/quotes/209081561/composite

$

130.00

Change

+1.17 +0.91%

Volume

Volume 5

Quotes are delayed by 20 min

/zigman2/quotes/209081561/composite

Previous close

$ 128.83

$ 128.83

Change

+2.85 +2.26%

Day low

Day high

$123.71

$129.32

Open

52 week low

52 week high

$106.13

$306.72

Open

Company Description

Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The firm products are directly sold to end users and distributo...

Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The firm products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.

Valuation

P/E Current

6.77

P/E Ratio (with extraordinary items)

6.78

P/E Ratio (without extraordinary items)

9.66

Price to Sales Ratio

4.71

Price to Book Ratio

5.70

Price to Cash Flow Ratio

12.44

Enterprise Value to EBITDA

6.59

Enterprise Value to Sales

4.49

Total Debt to Enterprise Value

0.02

Efficiency

Revenue/Employee

1,212,896.00

Income Per Employee

591,450.00

Receivables Turnover

5.22

Total Asset Turnover

1.17

Liquidity

Current Ratio

3.39

Quick Ratio

3.05

Cash Ratio

1.45

Profitability

Gross Margin

81.17

Operating Margin

64.12

Pretax Margin

62.61

Net Margin

48.76

Return on Assets

56.85

Return on Equity

85.63

Return on Total Capital

100.39

Return on Invested Capital

77.36

Capital Structure

Total Debt to Total Equity

8.47

Total Debt to Total Capital

7.81

Total Debt to Total Assets

5.91

Long-Term Debt to Equity

7.86

Long-Term Debt to Total Capital

7.25

Officers and Executives

Name Age Officer Since Title
Mr. Douglas C. Bryant 61 2009 President, Chief Executive Officer & Director
Mr. Robert Joseph Bujarski 50 2005 Secretary & Senior VP-Business Development
Mr. Randall J. Steward 64 2011 Chief Financial Officer
Dr. Werner Kroll 62 2014 Senior Vice President-Research & Development
Ms. Karen S. Gibson 56 - SVP-Information Systems & Business Transformation

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/30/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
216   Derivative/Non-derivative trans. at $126.39 per share. 27,300
03/30/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
434   Derivative/Non-derivative trans. at $0 per share. 0
03/17/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
2,799   Disposition at $136.05 per share. 380,803
03/17/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
4,601   Disposition at $136.07 per share. 626,058
03/17/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
3,910   Derivative/Non-derivative trans. at $15.4 per share. 60,214
03/17/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
691   Derivative/Non-derivative trans. at $23.41 per share. 16,176
02/24/2021 Werner Kroll
SVP, R&D
5,283   Disposition at $173.71 per share. 917,709
02/23/2021 Werner Kroll
SVP, R&D
173   Disposition at $164.59 per share. 28,474
02/23/2021 Werner Kroll
SVP, R&D
4,662   Disposition at $166.36 per share. 775,570
02/22/2021 Douglas C. Bryant
President & CEO; Director
5,000   Acquisition at $165.3 per share. 826,500
02/22/2021 Werner Kroll
SVP, R&D
3,926   Derivative/Non-derivative trans. at $59.12 per share. 232,105
02/22/2021 Werner Kroll
SVP, R&D
2,970   Derivative/Non-derivative trans. at $47.85 per share. 142,114
02/22/2021 Werner Kroll
SVP, R&D
2,303   Derivative/Non-derivative trans. at $46.41 per share. 106,882
02/22/2021 Werner Kroll
SVP, R&D
3,585   Derivative/Non-derivative trans. at $21.08 per share. 75,571
02/22/2021 Werner Kroll
SVP, R&D
12,784   Disposition at $164.11 per share. 2,097,982
02/18/2021 Douglas C. Bryant
President & CEO; Director
9,282   Derivative/Non-derivative trans. at $210.1 per share. 1,950,148
02/18/2021 Douglas C. Bryant
President & CEO; Director
6,851   Derivative/Non-derivative trans. at $210.1 per share. 1,439,395
02/18/2021 Edward Kieth Russell
SVP, Business Development
1,797   Derivative/Non-derivative trans. at $210.1 per share. 377,549
02/18/2021 Edward Kieth Russell
SVP, Business Development
2,284   Derivative/Non-derivative trans. at $210.1 per share. 479,868
02/18/2021 Robert Joseph Bujarski
Chief Operating Officer
1,797   Derivative/Non-derivative trans. at $210.1 per share. 377,549
02/18/2021 Robert Joseph Bujarski
Chief Operating Officer
2,284   Derivative/Non-derivative trans. at $210.1 per share. 479,868
02/18/2021 Randall J. Steward
Chief Financial Officer
2,396   Derivative/Non-derivative trans. at $210.1 per share. 503,399
02/18/2021 Randall J. Steward
Chief Financial Officer
2,379   Derivative/Non-derivative trans. at $210.1 per share. 499,827
02/18/2021 Tamara A Ranalli
SVP, Molecular Bus. Unit
585   Derivative/Non-derivative trans. at $210.1 per share. 122,908
02/18/2021 Tamara A Ranalli
SVP, Molecular Bus. Unit
421   Derivative/Non-derivative trans. at $210.1 per share. 88,452
02/18/2021 Werner Kroll
SVP, R&D
2,016   Derivative/Non-derivative trans. at $210.1 per share. 423,561
02/18/2021 Werner Kroll
SVP, R&D
2,366   Derivative/Non-derivative trans. at $210.1 per share. 497,096
02/18/2021 Karen C. Gibson
SVP, Digital Health
824   Derivative/Non-derivative trans. at $210.1 per share. 173,122
02/18/2021 Karen C. Gibson
SVP, Digital Health
857   Derivative/Non-derivative trans. at $210.1 per share. 180,055
02/18/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
824   Derivative/Non-derivative trans. at $210.1 per share. 173,122
02/18/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
633   Derivative/Non-derivative trans. at $210.1 per share. 132,993
02/18/2021 Douglas C. Bryant
President & CEO; Director
18,720   Award at $0 per share. 0
02/18/2021 Douglas C. Bryant
President & CEO; Director
13,818   Award at $0 per share. 0
02/18/2021 Edward Kieth Russell
SVP, Business Development
3,623   Award at $0 per share. 0
02/18/2021 Edward Kieth Russell
SVP, Business Development
4,606   Award at $0 per share. 0
02/18/2021 Robert Joseph Bujarski
Chief Operating Officer
3,623   Award at $0 per share. 0
02/18/2021 Robert Joseph Bujarski
Chief Operating Officer
4,606   Award at $0 per share. 0
02/18/2021 Randall J. Steward
Chief Financial Officer
4,831   Award at $0 per share. 0
02/18/2021 Randall J. Steward
Chief Financial Officer
4,798   Award at $0 per share. 0
02/18/2021 Tamara A Ranalli
SVP, Molecular Bus. Unit
1,510   Award at $0 per share. 0
02/18/2021 Tamara A Ranalli
SVP, Molecular Bus. Unit
1,727   Award at $0 per share. 0
02/18/2021 Werner Kroll
SVP, R&D
3,925   Award at $0 per share. 0
02/18/2021 Werner Kroll
SVP, R&D
4,606   Award at $0 per share. 0
02/18/2021 Karen C. Gibson
SVP, Digital Health
1,661   Award at $0 per share. 0
02/18/2021 Karen C. Gibson
SVP, Digital Health
1,727   Award at $0 per share. 0
02/18/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
1,661   Award at $0 per share. 0
02/18/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
1,727   Award at $0 per share. 0
02/17/2021 Douglas C. Bryant
President & CEO; Director
1,393   Derivative/Non-derivative trans. at $217.79 per share. 303,381
02/17/2021 Douglas C. Bryant
President & CEO; Director
4,423   Derivative/Non-derivative trans. at $217.79 per share. 963,285
02/17/2021 Robert Joseph Bujarski
Chief Operating Officer
543   Derivative/Non-derivative trans. at $217.79 per share. 118,259
02/17/2021 Robert Joseph Bujarski
Chief Operating Officer
1,723   Derivative/Non-derivative trans. at $217.79 per share. 375,252
02/17/2021 Werner Kroll
SVP, R&D
542   Derivative/Non-derivative trans. at $217.79 per share. 118,042
02/17/2021 Werner Kroll
SVP, R&D
1,725   Derivative/Non-derivative trans. at $217.79 per share. 375,687
02/17/2021 Douglas C. Bryant
President & CEO; Director
2,808   Award at $0 per share. 0
02/17/2021 Douglas C. Bryant
President & CEO; Director
9,363   Award at $0 per share. 0
02/17/2021 Robert Joseph Bujarski
Chief Operating Officer
1,094   Award at $0 per share. 0
02/17/2021 Robert Joseph Bujarski
Chief Operating Officer
3,646   Award at $0 per share. 0
02/17/2021 Werner Kroll
SVP, R&D
1,055   Award at $0 per share. 0
02/17/2021 Werner Kroll
SVP, R&D
3,519   Award at $0 per share. 0
02/15/2021 Douglas C. Bryant
President & CEO; Director
10,040   Derivative/Non-derivative trans. at $227.97 per share. 2,288,818
02/15/2021 Edward Kieth Russell
SVP, Business Development
3,470   Derivative/Non-derivative trans. at $227.97 per share. 791,055
02/15/2021 Robert Joseph Bujarski
Chief Operating Officer
3,556   Derivative/Non-derivative trans. at $227.97 per share. 810,661
02/15/2021 Randall J. Steward
Chief Financial Officer
3,766   Derivative/Non-derivative trans. at $227.97 per share. 858,535
02/15/2021 Tamara A Ranalli
SVP, Molecular Bus. Unit
165   Derivative/Non-derivative trans. at $227.97 per share. 37,615
02/15/2021 Werner Kroll
SVP, R&D
3,683   Derivative/Non-derivative trans. at $227.97 per share. 839,613
02/15/2021 Karen C. Gibson
SVP, Digital Health
1,883   Derivative/Non-derivative trans. at $227.97 per share. 429,267
02/15/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
234   Derivative/Non-derivative trans. at $227.97 per share. 53,344
02/15/2021 Douglas C. Bryant
President & CEO; Director
20,250   Award at $0 per share. 0
02/15/2021 Edward Kieth Russell
SVP, Business Development
7,172   Award at $0 per share. 0
02/15/2021 Robert Joseph Bujarski
Chief Operating Officer
7,172   Award at $0 per share. 0
02/15/2021 Randall J. Steward
Chief Financial Officer
7,594   Award at $0 per share. 0
02/15/2021 Tamara A Ranalli
SVP, Molecular Bus. Unit
675   Award at $0 per share. 0
02/15/2021 Werner Kroll
SVP, R&D
7,172   Award at $0 per share. 0
02/15/2021 Karen C. Gibson
SVP, Digital Health
3,797   Award at $0 per share. 0
02/15/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
675   Award at $0 per share. 0
02/04/2021 Werner Kroll
SVP, R&D
2,192   Derivative/Non-derivative trans. at $228.68 per share. 501,266
02/04/2021 Werner Kroll
SVP, R&D
4,268   Award at $0 per share. 0
02/03/2021 Douglas C. Bryant
President & CEO; Director
1,882   Derivative/Non-derivative trans. at $236.85 per share. 445,751
02/03/2021 Edward Kieth Russell
SVP, Business Development
575   Derivative/Non-derivative trans. at $236.85 per share. 136,188
02/03/2021 Robert Joseph Bujarski
Chief Operating Officer
791   Derivative/Non-derivative trans. at $236.85 per share. 187,348
02/03/2021 Randall J. Steward
Chief Financial Officer
2,498   Derivative/Non-derivative trans. at $236.85 per share. 591,651
02/03/2021 Tamara A Ranalli
SVP, Molecular Bus. Unit
145   Derivative/Non-derivative trans. at $236.85 per share. 34,343
02/03/2021 Karen C. Gibson
SVP, Digital Health
824   Derivative/Non-derivative trans. at $236.85 per share. 195,164
02/03/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
226   Derivative/Non-derivative trans. at $236.85 per share. 53,528
02/03/2021 Douglas C. Bryant
President & CEO; Director
3,795   Award at $0 per share. 0
02/03/2021 Edward Kieth Russell
SVP, Business Development
1,661   Award at $0 per share. 0
02/03/2021 Robert Joseph Bujarski
Chief Operating Officer
1,661   Award at $0 per share. 0
02/03/2021 Randall J. Steward
Chief Financial Officer
5,616   Award at $0 per share. 0
02/03/2021 Tamara A Ranalli
SVP, Molecular Bus. Unit
593   Award at $0 per share. 0
02/03/2021 Karen C. Gibson
SVP, Digital Health
1,661   Award at $0 per share. 0
02/03/2021 William J. Ferenczy
SVP, Cardio/Metabolic Unit
653   Award at $0 per share. 0
/news/latest/company/us/qdel

MarketWatch News on QDEL

  1. Quidel upgraded to outperform from market perform at Raymond James

    8:37 a.m. Jan. 22, 2021

    - Tomi Kilgore

  2. Abbott Gets the First Big Orders for Its Fast Covid Test

    3:10 p.m. Sept. 29, 2020

    - Barron's Online

  3. The Pandemic Speeds Up the Health-Care Revolution

    6:01 p.m. Oct. 6, 2020

    - Barron's Online

  4. Quidel downgraded to underweight from neutral at J.P. Morgan

    7:53 a.m. May 12, 2020

    - Tomi Kilgore

  5. Quidel stock price target raised to $158 from $120 at J.P. Morgan

    7:54 a.m. May 12, 2020

    - Tomi Kilgore

  6. Trump Team Signals Optimism Sunday, Despite Grim News

    2:57 p.m. May 10, 2020

    - Barron's Online

  7. U.S. states move to expand coronavirus testing

    5:06 p.m. May 9, 2020

    - Ben Chapman

  8. FDA grants emergency-use status for first coronavirus antigen test

    11:34 a.m. May 9, 2020

    - Thomas M. Burton

  9. How to profit from the ‘best of both worlds’ in stock investing

    10:20 a.m. Sept. 23, 2019

    - Philip van Doorn

  10. Quidel Corp.maintained as strong buy at Raymond James

    8:09 a.m. May 30, 2019

    - Ciara Linnane

  11. Quidel Corp. price target cut to $70 from $80 at Raymond James

    9:57 a.m. Dec. 11, 2018

    - Tonya Garcia

  12. Quidel upgraded to strong buy from outperform at Raymond James

    9:42 a.m. March 8, 2018

    - Tomi Kilgore

  13. Expect better, more reliable flu tests

    9:12 a.m. Feb. 24, 2018

    - MarketWatch.com

  14. Charting the Market

    12:13 a.m. July 22, 2017

    - Barron's Online

  15. Quidel upgraded to outperform from market perform at Raymond James

    8:13 a.m. June 13, 2016

    - Tomi Kilgore

  16. Loading more headlines...
/news/nonmarketwatch/company/us/qdel

Other News on QDEL

  1. Fulgent Genetics: Sell This Covid-19 Stock Before Its Earnings Slump

    37 min ago

    - Seeking Alpha

  2. Healthcare Dashboard For April And Focus On IDNA

    1:23 p.m. April 15, 2021

    - Seeking Alpha

  3. Quidel (QDEL) Stock Moves -0.28%: What You Should Know

    5:45 p.m. April 14, 2021

    - Zacks.com

  4. Quidel: Growth Beyond COVID-19

    6:14 p.m. April 13, 2021

    - Seeking Alpha

  5. Best And Worst Performing Midcap Stocks In Q1 2021

    2:07 p.m. April 6, 2021

    - Seeking Alpha

  6. What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

    5:18 p.m. April 1, 2021

    - InvestorPlace.com

  7. Why Fulgent Genetics Is a Great Stock to Buy Right Now

    6:54 a.m. March 31, 2021

    - Motley Fool

  8. These 3 Stocks Will Make You Rethink Your Portfolio

    6:40 a.m. March 30, 2021

    - Motley Fool

  9. Quidel (QDEL) Gains But Lags Market: What You Should Know

    5:45 p.m. March 26, 2021

    - Zacks.com

  10. Covid Fatigue Threatens to Derail Once Relevant Quidel

    12:12 p.m. March 26, 2021

    - InvestorPlace.com

  11. Bull of the Day: Meridian Bioscience (VIVO)

    5:20 a.m. March 22, 2021

    - Zacks.com

  12. Did 'What Works On Wall Street' Stop Working?

    7:52 p.m. March 16, 2021

    - Seeking Alpha

  13. Loading more headlines...

At a Glance

Quidel Corp.

9975 Summers Ridge Road

San Diego, California 92121

Phone

1 8585521100

Industry

Medical Equipment/Supplies

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$1.66B

Net Income

$810.29M

2020 Sales Growth

210.7%

Employees

1,370

/news/pressrelease/company/us/qdel

Press Releases on QDEL

  1. Tuesday 2/23 Insider Buying Report: QDEL, XAIR

    1:35 p.m. Feb. 23, 2021

    - MarketNewsVideo.com

  2. Tuesday's ETF with Unusual Volume: XMMO

    12:12 p.m. Feb. 23, 2021

    - MarketNewsVideo.com

  3. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.